scholarly article | Q13442814 |
P356 | DOI | 10.1111/CEA.12275 |
P698 | PubMed publication ID | 24447114 |
P50 | author | Helmut Küchenhoff | Q52699954 |
Andreas Bender | Q43680511 | ||
P2093 | author name string | K Sotlar | |
H-P Horny | |||
F Ruëff | |||
B Przybilla | |||
M Flaig | |||
R Chatelain | |||
S Dugas-Breit | |||
B Vos | |||
A Linhardt | |||
E Stretz | |||
J Oude Elberink | |||
R Vollrath | |||
S Mastnik | |||
P2860 | cites work | Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses | Q43821997 |
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels | Q43992711 | ||
Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice | Q46787767 | ||
Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema | Q47814416 | ||
Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. | Q50871797 | ||
Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety | Q52445480 | ||
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. | Q52687592 | ||
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensiti | Q52699890 | ||
Influence of total and specific IgE, serum tryptase, and age on severity of allergic reactions to Hymenoptera stings | Q52709943 | ||
A new look at the statistical model identification | Q26778401 | ||
Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 | ||
Stinging insect hypersensitivity: a practice parameter update 2011. | Q34175153 | ||
Clinical features and severity grading of anaphylaxis | Q34341881 | ||
Diagnosis of Hymenoptera venom allergy | Q34561401 | ||
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity | Q34735017 | ||
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal | Q35574171 | ||
Mastocytosis and Hymenoptera venom allergy | Q36529604 | ||
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria | Q36835061 | ||
Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy | Q37559690 | ||
Mastocytosis and insect venom allergy | Q37756473 | ||
Diagnosis and treatment of allergy to hymenoptera venoms | Q37764668 | ||
Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. | Q37873485 | ||
Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. | Q37876117 | ||
New topics in bradykinin research. | Q37920922 | ||
Incidence and severity of anaphylactoid reactions to colloid volume substitutes | Q39423931 | ||
Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines | Q39716681 | ||
Discontinuing venom immunotherapy: extended observations | Q41731183 | ||
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. | Q41987845 | ||
Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy | Q42447122 | ||
Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings | Q43531335 | ||
P433 | issue | 5 | |
P921 | main subject | Hymenoptera | Q22651 |
immunotherapy | Q1427096 | ||
venom | Q3386847 | ||
P304 | page(s) | 736-746 | |
P577 | publication date | 2014-01-01 | |
P1433 | published in | Clinical & Experimental Allergy | Q5133747 |
P1476 | title | Predictors of clinical effectiveness of Hymenoptera venom immunotherapy | |
P478 | volume | 44 |
Q34500152 | 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines |
Q38364807 | Anaphylaxis and cardiovascular disease: therapeutic dilemmas |
Q42476004 | Anaphylaxis with clonal mast cells in normal looking skin - a new entity? |
Q52769907 | Changing practice: no need to stop ACE inhibition for venom immunotherapy. |
Q89537659 | Clinical Utility of Rush Venom Immunotherapy: Current Status |
Q34669524 | Clinical contraindications to allergen immunotherapy: an EAACI position paper |
Q40940984 | Developments in the field of allergy in 2014 through the eyes of Clinical and Experimental Allergy. |
Q38658310 | EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy. |
Q93186376 | Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings? |
Q37608704 | Hymenoptera allergens: from venom to "venome". |
Q35153623 | Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. |
Q38627901 | Overcoming severe adverse reactions to venom immunotherapy by using anti-IgE antibodies in combination with a high maintenance dose |
Q30371972 | Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement |
Q33645878 | Safety and efficacy of venom immunotherapy: a real life study |
Q104616203 | Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy) |
Q51533907 | Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement. |
Q49821513 | Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol |
Q38505192 | Venom immunotherapy: clinical efficacy, safety and contraindications. |
Q91176197 | Worldwide perspectives on venom allergy |
Q52779212 | [Sting challenge: indications and execution]. |
Search more.